Home / Market News / $NKTR
benzinga Corporate Catalyst Impact 55/100 ● neutral

BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target

Oct 9, 2026, 5:13 PM UTC · Primary ticker $NKTR

This filing discloses that BTIG analyst Julian Harrison has reiterated a 'Buy' rating and maintained a $178 price target for Nektar Therapeutics. This indicates continued analyst confidence in the company's prospects, which could provide some positive sentiment for investors.

BTIG analyst Julian Harrison has reaffirmed a 'Buy' rating and a $178 price target for Nektar Therapeutics. This action signals that the analyst's investment thesis for NKTR remains unchanged and positive. For traders, this reiteration could provide a short-term boost in investor confidence, potentially leading to some upward price movement or stabilization. However, as it's a reiteration rather than a new rating or significant change, its long-term impact might be limited unless it's part of a broader trend of positive analyst coverage. The key opportunity for traders lies in identifying if this reiteration acts as a catalyst for renewed interest in NKTR, especially if the stock has been under pressure.

$NKTR positive Analyst reiterates Buy rating and price target
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.